SCHEMBL17048890

SCHEMBL17048890

CCOC(=O)C1CCC(=O)CC1(C)C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PSEN1 P49768 1/20 0.39
PSEN2 P49810 1/20 0.39
APH1B Q8WW43 1/20 0.39
NCSTN Q92542 1/20 0.39
APH1A Q96BI3 1/20 0.39
PSENEN Q9NZ42 1/20 0.39
TP53 P04637 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
ALDH1A1 P00352 4/20 0.36
MAPT P10636 3/20 0.36
KDM4E B2RXH2 1/20 0.36
MEN1 O00255 1/20 0.36
GAA P10253 1/20 0.36
HPGD P15428 1/20 0.36
KMT2A Q03164 1/20 0.36
HSD17B10 Q99714 1/20 0.36
TSHR P16473 2/20 0.35
HTT P42858 1/20 0.35
HIF1A Q16665 1/20 0.35
NPC1 O15118 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17118118 1.00 PSEN1 (0.39) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL2014327 0.83 PSEN1 (0.38) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL812651 0.83 PSEN1 (0.36) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL2013946 0.81 ATM (0.37) ALDH1A1MAPTGAAKMT2ATSHR
SCHEMBL2505350 0.81 ATM (0.37) ALDH1A1MAPTGAAKMT2ATSHR
SCHEMBL19759347 0.77 MAPK1 (0.39) GAA
SCHEMBL2017466 0.75 SLC1A2 (0.34) MEN1KMT2AHTT
SCHEMBL17110217 0.75 AKR1B10 (0.36) SMN1; SMN2ALDH1A1MAPTKDM4EMEN1
SCHEMBL2017042 0.75 SLC1A2 (0.34) MEN1KMT2AHTT
SCHEMBL294716 0.73 LMNA (0.43) ALDH1A1MAPTKDM4EMEN1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240417386-A1 INHIBITORS OF RET MIDCAP FINANCIAL TRUST 2024-12-19 US disclosed
EP-4331585-A2 INHIBITORS OF RET Blueprint Medicines Corporation (US) 2024-03-06 EP disclosed
EP-4292594-A2 INHIBITORS OF RET Blueprint Medicines Corporation (US) 2023-12-20 EP disclosed
EP-3371171-B1 INHIBITORS OF RET BLUEPRINT MEDICINES CORP (US) 2023-10-25 EP disclosed
EP-3371171-B1 INHIBITORS OF RET BLUEPRINT MEDICINES CORP (US) 2023-10-25 EP disclosed
CN-111423416-B Inhibitors of RET 缆图药品公司 2023-05-26 CN disclosed
US-20220315560-A1 INHIBITORS OF RET BLUEPRINT MEDICINES CORPORATION 2022-10-06 US disclosed
US-11279688-B2 Inhibitors of RET BLUEPRINT MEDICINES CORPORATION (US) 2022-03-22 US disclosed
US-20200407341-A1 INHIBITORS OF RET BLUEPRINT MEDICINES CORPORATION 2020-12-31 US disclosed
CN-111423416-A Inhibitors of RET 蓝图药品公司 2020-07-17 CN disclosed
EP-3110810-B1 PYRAZOLE AMIDE DERIVATIVE TEIJIN PHARMA LTD (JP) 2018-05-02 EP disclosed
WO-2017079140-A1 INHIBITORS OF RET BLUEPRINT MEDICINES CORPORATION (US) 2017-05-11 WO disclosed
WO-2017079140-A1 INHIBITORS OF RET BLUEPRINT MEDICINES CORPORATION (US) 2017-05-11 WO disclosed
US-20170121312-A1 INHIBITORS OF RET BLUEPRINT MEDICINES CORPORATION 2017-05-04 US disclosed
US-20170121312-A1 INHIBITORS OF RET BLUEPRINT MEDICINES CORPORATION 2017-05-04 US disclosed
US-20170121312-A1 INHIBITORS OF RET BLUEPRINT MEDICINES CORPORATION 2017-05-04 US disclosed
EP-3110810-A1 PYRAZOLE AMIDE DERIVATIVE Teijin Pharma Limited (JP) 2017-01-04 EP disclosed
US-9365522-B2 Pyrazole amide derivative AMGEN INC. (US) 2016-06-14 US disclosed
US-20150266824-A1 Pyrazole Amide Derivative TEIJIN LIMITED (JP) 2015-09-24 US disclosed
WO-2015129926-A1 PYRAZOLE AMIDE DERIVATIVE TEIJIN PHARMA LIMITED (JP) 2015-09-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240417386-A1 INHIBITORS OF RET RET, HRAS, RB1 PSEN1 1989/4885PSEN2 1289/4885APH1B 1933/4885
US-11279688-B2 Inhibitors of RET RET, HRAS, RB1 PSEN1 1989/4885PSEN2 1289/4885APH1B 1933/4885
US-20150266824-A1 Pyrazole Amide Derivative RORC, RORB, RORA PSEN1 4571/4885PSEN2 4516/4885APH1B 2905/4885
US-20200407341-A1 INHIBITORS OF RET RET, HRAS, RB1 PSEN1 1989/4885PSEN2 1289/4885APH1B 1933/4885
US-20170121312-A1 INHIBITORS OF RET RET, HRAS, RB1 PSEN1 1989/4885PSEN2 1289/4885APH1B 1933/4885
US-20220315560-A1 INHIBITORS OF RET RET, HRAS, RB1 PSEN1 1989/4885PSEN2 1289/4885APH1B 1933/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.